No Slowdown From Bayer On Business Development Front
Since 2015, Invested $1.7bn In Over 55 Start-ups
“We're looking at opportunities almost on a weekly basis,” Bayer’s pharma chief Stefan Oelrich told Scrip as the German major posted a solid set of financials for the fourth quarter.
